Structure-activity relationships studies in a series of N,N-bis(alkanol)amine aryl esters as P-glycoprotein (Pgp) dependent multidrug resistance (MDR) inhibitors

Journal of Medicinal Chemistry

Volumn 53, Issue 4, 2010, Pages 1755-1762

  Martelli, Cecilia ^a   Coronnello, Marcella ^a   Dei, Silvia ^a   Manetti, Dina ^a   Orlandi, Francesca ^a   Scapecchi, Serena ^a   Romanelli, Maria Novella ^a   Salerno, Milena ^b   Mini, Enrico ^a   Teodori, Elisabetta ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITÉ PARIS 13   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACENE DERIVATIVE; DOXORUBICIN; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; PIRARUBICIN;

ARTICLE; CANCER GROWTH; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG SYNTHESIS; ERYTHROLEUKEMIA; HUMAN; HUMAN CELL; STRUCTURE ACTIVITY RELATION;

AMINES; ANTINEOPLASTIC AGENTS; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ESTERS; HUMANS; K562 CELLS; P-GLYCOPROTEIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77649203312     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm9016174     Document Type: Article

References (50)

1. Ito, K.; Suzuki, H.; Horie, T.; Sugiyama, Y. Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport. Pharm. Res. 2005, 22, 1559-1577.
2. Linton, K. J. Structure and function of ABC transporters. Physiology 2007, 22, 122-130.
3. Kuhnke, D.; Jedlitschky, G.; Grube, M.; Krohn, M.; Juker, M.; Mosyagin, I.; Cascorbi, I.; Walker, L. C.; Kroemer, H. K.; Warzog, R. W.; Vogelgesang, S. MDR1-P-Glycoprotein (ABCB1) mediates transport of Alzheimer's amyloid-beta peptides - implications for the mechamism of Abeta clearance at the blood-brain barrier. Brain Pathol. 2007, 17, 347-353.
4. Johnstone, R. W.; Ruefli, A. A.; Smyth, M. J. Multiple physiological functions for multidrug transporter P-glycoprotein? Trends Biochem. Sci. 2000, 25, 1-6.
5. Mitscher, L. A.; Pillai, S. P.; Gentry, E. J.; Shankel, D. M. Multiple drug resistance. Med. Res. Rev. 1999, 19, 477-496.
6. Volm, M.; Mattern, J. Resistance mechanisms and their regulation in lung cancer. Crit. Rev. Oncog. 1996, 7, 227-244.
7. Aszalos, A.; Ross, D. D. Biochemical and clinical aspects of efflux pump related resistance to anti-cancer drugs. Anticancer Res. 1998, 18, 2937-2944.
8. Dean, M. ABC Transporters, Drug Resistance, and Cancer Stem cells. J. Mammary Gland Biol. Neoplasia 2009, 14, 3-9.
9. Teodori, E.; Dei, S.; Martelli, C.; Scapecchi, S.; Gualtieri, F. The functions and structure of ABC transporters: implications for the design of new inhibitors of Pgp and MRP1 to control multidrug resistance (MDR). Curr. Drug Targets 2006, 7, 893-909.
10. Avendano, C.; Menendez, J. C. Recent advances in multidrug resistance modulators. Med. Chem. Rev.-Online 2004, 1, 419-444.
11. Robert, J.; Jarry, C. Multidrug resistance reversal agents. J. Med. Chem. 2003, 46, 4805-4817.
12. Nobili, S.; Landini, I.; Giglioni, B.; Mini, E. Pharmacological strategies for overcoming multidrug resistance. Curr. Drug Targets 2006, 7, 861-879.
13. Fusi, F.; Saponara, S.; Valoti, M.; Dragoni, S.; D'Elia, P.; Sgaragli, T.; Alderighi, D.; Kawase, M.; Shah, A.; Motohashi, N.; Sgaragli, G. Cancer cell permeability-glycoprotein as a target of MDR reverters: possible role of novel dihydropyridine derivatives. Curr. Drug Targets 2006, 8, 949-959. (Pubitemid 44227579)
14. Sorbera, L. A.; Castaner, J.; Silvestre, J. S.; Bayés, M. Zosuquidar trihydrochloride. Drugs Future 2003, 28, 125-136.
15. Tan, B.; Piwnica-Worms, D.; Ratner, L. Multidrug resistance transporters and modulation. Curr. Opin. Oncol. 2000, 12, 450-458.
16. Robey, R. W.; Lazarowski, A.; bates, S. E. P-Glycoprotein - a clinical target in drug-refractory epilepsy? Mol. Pharmacol. 2008, 73, 1343-1346.
17. Owen, A.; Chandler, B.; Back, D. J. The implications of Pglycoprotein in HIV: friend or foe? Fund. Clin. Pharmacol. 2005, 19, 283-296.
18. Rosenberg, M. F.; Kamis, A. B.; Callaghan, R.; Higgins, C. F.; Ford, R. C. Three dimensional structures of the mammalian multidrug-resistant P-glycoprotein demonstrate major conformational changes in the transmembrane domain upon nucleotide binding. J. Biol. Chem. 2003, 278, 8294-8299.
19. Rosenberg, M. F.; Callaghan, R.; Modok, S.; Higgins, C. F.; Ford, R. C. Three-dimensional structure of P-glycoprotein. J. Biol. Chem. 2005, 280, 2857-2862.
20. Ward, A.; Reyes, C. L.; Yu, J.; Roth, C. B.; Chang, G. Flexibility in the ABC transporter MsbA: alternating access with a twist. Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 19005-19010.
21. Dawson, R. J. P.; Locher, K. P. Structure of the multidrug ABC transporter Sav1866 from Staphylococcus aureus in complex with AMP-PNP. FEBS Lett. 2007, 581, 935-938.
22. Zolnerciks, J. K.; Wooding, C.; Linton, K. J. Evidence for a Sav1866-like architecture for the human multidrug transporter Pglycoprotein. FASEB J. 2007, 21, 3937-3948.
23. O'Mara, M. L.; Tieleman, D. P. P-Glycoprotein models of the apo and ATP-bound states based on homology with Sav1866 and Ma1K. FEBS Lett. 2007, 581, 4217-4222.
24. Globish, C.; Pajeva, I. K.; Wiese, M. Identification of putative binding sits of P-glycoprotein based on its homology models. ChemMedChem 2008, 3, 280-295.
25. Gottesman, M. M.; Fojo, T.; Bates, S. E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nature Rev. Cancer 2002, 2, 48-58. (Pubitemid 37328807)
26. Murray, D. S.; Schumacher, M. A.; Brennan, R. G. Crystal structure of QacR-diamidine complexes reveal additional multidrug-binding modes and a novel mechanism of drug charge neutralization. J. Biol. Chem. 2004, 279, 14365-14371.
27. Schumacher, M. A.; Miller, M. C.; Brennan, R. G. Structural mechanism of the simultaneous binding of two drugs to a multidrug binding protein. EMBO J. 2004, 23, 2923-2930.
28. Aller, S. G.; Yu, J.; Ward, A.; Weng, Y.; Chittaboina, S.; Zhuo, R.; Harrell, P. M.; Trinh, Y. T.; Zhang, Q.; Urbatsch, I. L.; Chang, G. Structure of P-glycoprotein reveals a molecular basis for polyspecific drug binding. Science 2009, 323, 1718-1722.
29. Teodori, E.; Dei, S.; Garnier-Suillerot, A.; Gualtieri, F.; Manetti, D.; Martelli, C.; Romanelli, M. N.; Scapecchi, S.; Paiwan, S.; Salerno, M. Exploratory chemistry toward the identification of a new class of MDR reverters inspired by pervilleine and verapamil models. J. Med. Chem. 2005, 48, 7426-7436.
30. Teodori, E.; Martelli, C.; Salerno, M.; Darghal, N.; Dei, S.; Garnier-Suillerot, A.; Gualtieri, F.; Manetti, D.; Scapecchi, S.; Romanelli, M. N. Isomeric N,N-bis(cyclohexanol)amine aryl esters: the discovery of a new class of highly potent Pgp-dependent multidrug resistance (MDR) inhibitors. J. Med. Chem. 2007, 50, 599-602.
31. Teodori, E.; Dei, S.; Quidu, P.; Budriesi, R.; Chiarini, A.; Garnier-Suillerot, A.; Gualtieri, F.; Manetti, D.; Romanelli, M. N.; Scapecchi, S. Design, synthesis, and in vitro activity of catamphiphilic reverters of multidrug resistance: discovery of a selective, highly efficacious chemosensitizer with potency in the nanomolar range. J. Med. Chem. 1999, 42, 1687-1697.
32. Dei, S.; Teodori, E.; Garnier-Suillerot, A.; Gualtieri, F.; Scapecchi, S.; Budriesi, R.; Chiarini, A. Structure-activity relationships and optimization of the selective MDR modulator 2-(3,4-dimethoxyphenyl)-5-(9-fluorenylamino)-2- (methylethyl) pentanenitrile (SC11) and its N-methyl derivative (SC17). Bioorg. Med. Chem. 2001, 9, 2673-2682.
33. Martelli, C.; Alderighi, D.; Coronnello, M.; Dei, S.; Frosini, M.; Le Bozec, B.; Manetti, D.; Neri, A.; Romanelli, M. N.; Salerno, M.; Scapecchi, S.; Mini, E.; Sgaragli, G.; Teodori, E. N,N-Bis-(cyclohexanol)amine Aryl Esters: A New Class of Highly Potent Transporter-Dependent Multidrug Resistance Inhibitors. J. Med. Chem. 2009, 52, 807-817.
34. Alibert, S.; Santelli-Rouvier, C.; Castaing, M.; Berthelot, M.; Spengler, G.; Molnar, J.; Barbe, J. Effects of a Series of Dihydroanthracene Derivatives on Drug Efflux in Multidrug Resistant Cancer Cells. Eur. J. Med. Chem. 2003, 38, 253-263.
35. Bisi, A.; Gobbi, S.; Rampa, A.; Velluti, F.; Piazzi, L.; Valenti, P.; Gyemant, N.; Molnar, J. New potent P-glycoprotein inhibitors carrying a polycyclic scaffold. J. Med. Chem. 2006, 49, 3049-3051.
36. Dodic, N.; Dumaitre, B.; Daugan, A.; Pianetti, P. Synthesis and Activity against Multidrug Resistance in Chinese Hamster Ovary Cells of New Acridone-4-carboxamides. J. Med. Chem. 1995, 38, 2418-2426.
37. Mistry, P.; Stewart, A. J.; Dangerfield, W.; Okiji, S.; Liddle, C.; Bootle, D.; Plumb, J. A.; Templeton, D.; Charlton, P. In Vitro and in Vivo Reversal of P-Glycoprotein-mediated Multidrug Resistance by a Novel Potent Modulator, XR9576. Cancer Res. 2001, 61, 749-758.
38. Arjunan, P.; Shymasundar, N.; Berlin, K. D.; Najjar, D.; Rockley, M. G. Syntheses of selected ε-(2- or 9-anthryl)alkanoic acids and certain esters-carbon-13 spin-lattice relaxation time measurements of methyl 5-(2-anthryl)pentanoate and methyl 7-(2-anthryl)-heptanoate. J. Org. Chem. 1981, 46, 626-629.
39. Collomb, D.; Chantegrel, B.; Deshayes, C. Chemoselectivity in the Rhodium(ll) Acetate Catalysed Decomposition of α-Diazo-β-keto- γ,δ-alkenyl-δ-aryl Compounds: Aromatic C-H Insertion Reaction or Wolff Rearrangement-Electrocydization. Tetrahedron 1996, 52, 10455-10472. (Pubitemid 26244736)
40. Wang, C.; Pan, X.; Liu, H.; Fu, Z.; Wei, X.; Yang, L. X. Synthesis and antitumor activity of 20-O-linked nitrogen-based camptothecin ester derivatives. Bioorg. Med. Chem. 2004, 12, 3657-3662.
41. Baarschers, W. H.; Vukmanich, J. P. The chemistry of some methoxychlor derivatives. Can. J. Chem. 1986, 64, 932-935.
42. Weber, E.; Finge, S.; Csoeregh, I. Modular Design of Hosts Involving a Rigid Succinimide Framework and N-Bonded Lateral Groups. Crystalline Inclusion Properties and Crystal Structures of Inclusion Compounds with Dioxane, MeOH, and DMF. J. Org. Chem. 1991, 56, 7281-7287.
43. 99mTc-MIBI in cells with P-glycoprotein-mediated and multidrug-resistance proteinassociated multidrug-resistance phenothype. Eur. J. Biochem. 1998, 252, 140-146.
44. Reungpatthanaphong, P.; Marbeuf-Gueye, C.; Le Moyec, L.; Salerno, M.; Garnier-Suillerot, A. Decrease of P-glycoprotein activity in K562/ADR cells by MβCD and filipin and lack of effect induced by cholesterol oxidase indicate that this transporter is not located in rafts. J. Bioenerg. Biomembr. 2004, 36, 533-543.
45. Lozzio, C. B.; Lozzio, B. B. Human chronic myelogenous leukemia cell line positive philadelphia chromosome. Blood 1975, 45, 321-334.
46. Tsuruo, T.; Ida, H.; Kawataba, H.; Oh-Hara, T.; Hamada, H.; Utakoji, T. Characteristics of resistance to adriamycin in human myelogeneous leukemia K562 resistant to adriamycin and in isolated clones. Jpn. J. Cancer Res. 1986, 77, 682-687.
47. Dei, S.; Budriesi, R.; Paiwan, S.; Ferraroni, M.; Chiarini, A.; Garnier-Suillerot, A.; Manetti, D.; Martelli, C.; Scapecchi, S.; Teodori, E. Diphenylcyclohexylamine derivatives as new potent multidrug resistant (MDR) modulators. Bioorg. Med. Chem. 2005, 13, 985-998.
48. Pereira, E.; Garnier-Suillerot, A. Correlation between the shortterm measurements of drug accumulation in living cells and the long-term growth inhibition. Biochem. Pharmacol. 1994, 47, 1851-1857.
49. Alley, M. C.; Scudiero, D. A.; Monks, A.; Hursey, M. L.; Czerwinski, M. J.; Fine, D. L.; Abbott, B. J.; Mayo, J. G.; Shoemaker, R. H.; Boyd, M. R. Feasibility of drug screening with panels of human tumour cell lines using a microculture tetrazolium assay. Cancer Res. 1988, 48, 589-601.
50. Mankehetkorn, S.; Garnier-Suillerot, A. The ability of verapamil to restore intracellular accumulation of anthracyclines in multidrug resistant cells depends on the kinetics of their uptake. Eur. J. Pharmacol. 1998, 343, 313-321.